• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人类对通过全身或黏膜途径接种的流感病毒疫苗的免疫反应。

Human immune responses to influenza virus vaccines administered by systemic or mucosal routes.

作者信息

Moldoveanu Z, Clements M L, Prince S J, Murphy B R, Mestecky J

机构信息

Department of Microbiology and Medicine, University of Alabama at Birmingham 35294, USA.

出版信息

Vaccine. 1995 Aug;13(11):1006-12. doi: 10.1016/0264-410x(95)00016-t.

DOI:10.1016/0264-410x(95)00016-t
PMID:8525683
Abstract

Healthy adult volunteers were immunized by parenteral or oral routes with trivalent inactivated influenza vaccine (A/Chile/1/83 (H1N1), A/Mississippi/1/85 (H3N2), and B/Ann Arbor/1/86), or intranasally with live attenuated, cold-adapted influenza type A/Texas/1/85 (H1N1) reassortant virus. In all volunteers, cells spontaneously secreting IgA, IgG or IgM antibodies specific to influenza virus were detected in peripheral blood on days 6-13 after immunization, and specific IgA, IgG and IgM antibodies to influenza vaccine were measured in sera and external secretions (saliva and nasal lavage). Following systemic immunization, a raise in specific antibodies of all isotypes was observed in sera beginning on day 13. Although small variations in IgA and IgM antibodies in saliva and nasal lavages were detected, antigen-specific IgG significantly increased between days 13 and 27. Intranasal administration of attenuated virus induced IgA and IgG antibodies in serum as well as in secretions. Serum antibodies were not substantially influenced by oral immunization, only a small increase in all isotypes was observed in volunteers' sera 21 days after ingestion of vaccine. However, in secretions, antigen-specific IgA and IgG responses were detected one week after immunization and reached a peak response on day 20. These studies show that different routes of immunization can be effective for the induction of specific antibodies, and support the concept of the common mucosal immune system in humans by demonstrating that the oral or intranasal administration of antigen-induced specific antibodies of IgA isotype in external secretions, preceded by the transient appearance in peripheral blood of specific antibody-producing cells.

摘要

健康成年志愿者通过肠胃外或口服途径接种三价灭活流感疫苗(A/智利/1/83(H1N1)、A/密西西比/1/85(H3N2)和B/安阿伯/1/86),或通过鼻内接种减毒活的、冷适应的甲型流感病毒A/得克萨斯/1/85(H1N1)重组病毒。在所有志愿者中,免疫后第6至13天在外周血中检测到自发分泌针对流感病毒的IgA、IgG或IgM抗体的细胞,并在血清和外分泌液(唾液和鼻腔灌洗液)中测量针对流感疫苗的特异性IgA、IgG和IgM抗体。全身免疫后,从第13天开始血清中所有同种型的特异性抗体均出现升高。虽然在唾液和鼻腔灌洗液中检测到IgA和IgM抗体有微小变化,但在第13天至27天之间抗原特异性IgG显著增加。鼻内接种减毒病毒在血清以及分泌液中诱导产生IgA和IgG抗体。口服免疫对血清抗体影响不大,在志愿者摄入疫苗21天后血清中所有同种型仅出现小幅升高。然而,在分泌液中,免疫后一周检测到抗原特异性IgA和IgG反应,并在第20天达到反应峰值。这些研究表明,不同的免疫途径对于诱导特异性抗体可能是有效的,并且通过证明口服或鼻内给予抗原在外分泌液中诱导产生IgA同种型的特异性抗体,且在外周血中先短暂出现特异性抗体产生细胞,支持了人类共同黏膜免疫系统的概念。

相似文献

1
Human immune responses to influenza virus vaccines administered by systemic or mucosal routes.人类对通过全身或黏膜途径接种的流感病毒疫苗的免疫反应。
Vaccine. 1995 Aug;13(11):1006-12. doi: 10.1016/0264-410x(95)00016-t.
2
In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory.在老年人中,减毒活甲型流感病毒疫苗在诱导血清或分泌性抗体或局部免疫记忆方面,并不比灭活病毒疫苗更具优势。
J Clin Microbiol. 1991 Mar;29(3):498-505. doi: 10.1128/jcm.29.3.498-505.1991.
3
Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.经鼻腔接种的灭活 H5 流感疫苗诱导的人体免疫应答。
Microbiol Immunol. 2020 Apr;64(4):313-325. doi: 10.1111/1348-0421.12775. Epub 2020 Mar 29.
4
IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration.IgA 聚合作用有助于经鼻内接种灭活流感疫苗后在上呼吸道黏膜实现高效的病毒中和。
Hum Vaccin Immunother. 2018 Jun 3;14(6):1351-1361. doi: 10.1080/21645515.2018.1438791. Epub 2018 Apr 9.
5
Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine.养老院老年人经鼻内或肌肉注射灭活流感疫苗后的局部和全身免疫反应
Vaccine. 2003 Mar 7;21(11-12):1180-6. doi: 10.1016/s0264-410x(02)00481-4.
6
Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.年轻成年人鼻内接种一剂或两剂灭活三价抗流感疫苗后的黏膜(SIgA)和血清(IgG)免疫反应。
Vaccine. 2004 Jun 30;22(20):2566-77. doi: 10.1016/j.vaccine.2003.12.018.
7
Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.细菌样颗粒佐以灭活流感抗原经鼻内给药诱导交叉保护性流感特异性抗体应答。
Vaccine. 2012 Jul 6;30(32):4884-91. doi: 10.1016/j.vaccine.2012.04.032. Epub 2012 Apr 23.
8
Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity.口服喷雾免疫可能是鼻内疫苗接种的一种替代方法,用于诱导全身抗体,但不能诱导鼻黏膜或细胞免疫。
Scand J Immunol. 2006 Mar;63(3):223-31. doi: 10.1111/j.1365-3083.2006.01730.x.
9
Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.烷基多糖苷,一种在鼻内裂解流感疫苗中极具前景的佐剂。
Hum Vaccin Immunother. 2017 Jun 3;13(6):1-9. doi: 10.1080/21645515.2016.1278098. Epub 2017 Jan 27.
10
Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine.接种减毒活流感 A 病毒疫苗或灭活流感 A 病毒疫苗的成年人中局部和全身抗体反应的产生及持续情况。
J Clin Microbiol. 1986 Jan;23(1):66-72. doi: 10.1128/jcm.23.1.66-72.1986.

引用本文的文献

1
Timing influences the impact of aryl hydrocarbon receptor activation on the humoral immune response to respiratory viral infection.芳基烃受体激活对呼吸道病毒感染体液免疫反应的影响与时间有关。
Toxicol Appl Pharmacol. 2024 Aug;489:117010. doi: 10.1016/j.taap.2024.117010. Epub 2024 Jun 18.
2
Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Patients with Moderate to Severe Asthma: The Phase 3b VECTOR Study.特泽佩umab对中重度哮喘患者季节性四价流感疫苗体液免疫反应的影响:3b期VECTOR研究
Pulm Ther. 2024 Mar;10(1):53-67. doi: 10.1007/s41030-023-00245-9. Epub 2023 Dec 8.
3
Pneumonic Plague Protection Induced by a Monophosphoryl Lipid A Decorated Yersinia Outer-Membrane-Vesicle Vaccine.
肺炎型鼠疫保护作用由单磷酰脂质 A 修饰的耶尔森菌外膜囊泡疫苗诱导产生。
Small. 2024 Apr;20(15):e2307066. doi: 10.1002/smll.202307066. Epub 2023 Nov 27.
4
Evaluation of Anti-S1 IgA Response to Different COVID-19 Vaccination Regimens.不同新冠疫苗接种方案的抗S1 IgA反应评估
Vaccines (Basel). 2023 Jun 19;11(6):1117. doi: 10.3390/vaccines11061117.
5
Fulminant type 1 diabetes developed after influenza split vaccination.在接种流感裂解疫苗后发生了暴发性1型糖尿病。
Endocrinol Diabetes Metab Case Rep. 2023 May 4;2023(2). doi: 10.1530/EDM-22-0342. Print 2023 May 1.
6
Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell and taste disorders.长期系统性和黏膜 SARS-CoV-2 IgA 应答及其与持续性嗅觉和味觉障碍的关系。
Front Immunol. 2023 Mar 8;14:1140714. doi: 10.3389/fimmu.2023.1140714. eCollection 2023.
7
Intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2 induces neutralizing salivary IgA.肌肉内注射 mRNA BNT162b2 疫苗可诱导针对 SARS-CoV-2 的唾液中和性 IgA。
Front Immunol. 2023 Jan 30;13:933347. doi: 10.3389/fimmu.2022.933347. eCollection 2022.
8
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.SARS-CoV-2 特异性鼻内 IgA 在 COVID-19 住院治疗 9 个月后消失,且不会因后续接种疫苗而产生。
EBioMedicine. 2023 Jan;87:104402. doi: 10.1016/j.ebiom.2022.104402. Epub 2022 Dec 19.
9
Heterologous Systemic Prime-Intranasal Boosting Using a Spore SARS-CoV-2 Vaccine Confers Mucosal Immunity and Cross-Reactive Antibodies in Mice as well as Protection in Hamsters.使用孢子型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)疫苗进行异源系统初免-鼻内加强免疫可在小鼠中诱导黏膜免疫和交叉反应性抗体,并在仓鼠中提供保护。
Vaccines (Basel). 2022 Nov 10;10(11):1900. doi: 10.3390/vaccines10111900.
10
Mucosal immunity: The missing link in comprehending SARS-CoV-2 infection and transmission.黏膜免疫:理解 SARS-CoV-2 感染和传播的缺失环节。
Front Immunol. 2022 Aug 17;13:957107. doi: 10.3389/fimmu.2022.957107. eCollection 2022.